Under the Internet medical wind, multinational pharmaceutical companies have bet on this field

"Pharmaceutical Network Industry Dynamics" According to the 2020 China Internet and Medical Industry Research Report, the data of medical and health apps will increase significantly in 2020, especially during the outbreak at the beginning of the year.
industry believes that behind the surge in data is the growing demand for unsoponsed visits from the public on a daily basis.
According to Haitong International's Investment Strategy for the Internet Healthcare Industry, china's online drug market is expected to reach 209 billion yuan by 2025, with health insurance expected to be about 89.3 billion yuan and commercial insurance expected to be about 65.1 billion yuan.
Judging from the growth rate of the Internet plus medical industry in the relevant data, the digital transformation of medical services in the form of Internet hospitals has become a historical trend, and cooperation between pharmaceutical companies and Internet medical enterprises is becoming more and more common, especially in the field of chronic diseases.
For example, in recent years, Merck has reached strategic cooperation with Tencent, Ping An Good Doctor, etc., with the intention of improving patients' access to medical care through digital platforms, exploring comprehensive digital medical solutions for chronic disease management, and promoting the healthy development of smart healthcare in China.
Sanofi also announced a strategic partnership with Tencent last year.
Sanofi said that between now and 2025, Sanofi will introduce more than 30 innovative drugs and vaccines into China.
's partnership with Tencent will focus on key disease areas such as rare diseases, neurology and diabetes, and better meet patients' needs in early screening and disease management digitally through the deep integration of the Internet and pharmaceutical industries.
Pfizer split the China team into three divisions and for the first time used Internet Healthcare as one of its independent divisions, reporting directly to the president of Proms China.
, Novarma, AstraZeneta, GSK and other multinational pharmaceutical companies have also been involved in Internet medical, or with local companies in the field of chronic diseases.
Of course, in addition to multinational enterprises, domestic enterprises such as Ali Health, JD.com Health and other Internet treatment platforms have been introduced online slow disease follow-up, continued services.
, for example, on February 13th Ali Health announced the launch of a "Slow Disease Benefits Program" with 50 pharmaceutical companies, covering thousands of drugs from more than 10 common diseases.
At present, in general, many pharmaceutical companies choose to cooperate with Internet medical companies, mainly because such cooperation can help pharmaceutical companies in the existing channels and business models to be strengthened, but also with more Internet medical companies to explore more new business models to achieve sustainable business development.
trend, there will be more and more cooperation between domestic and foreign pharmaceutical companies and Internet medical platforms in the future.
addition, with the development of national drug collection, enterprises must reconsider the layout of research and development, marketing and product structure adjustment.
, domestic pharmaceutical companies are destined to accelerate the transition to professional promotion, as well as to the direction of the Internet plus.
the same time, the reshuffle of China's pharmaceutical market will be further promoted.